Celgene Corporation's competitors

Celgene Corporation's competitors include Gilead Sciences, Amgen, Shire and Eiger BioPharmaceuticals
Add company...
Celgene Corporation
Celgene Corporation is a biopharmaceutical company.
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Amgen
Amgen engages in the development of human therapeutic products in supportive of cancer care, inflammation, nephrology and bone diseases.
Shire
Shire is a specialty biopharmaceutical company.
Eiger BioPharmaceuticals
Eiger is a biopharmaceutical company developing new antiviral agents against novel targets in the treatment of hepatitis.
Founding Date
Founding Date
1986
Founding Date
1987
Founding Date
1980
Founding Date
1986
Founding Date
2008
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Summit, US HQ
Singapore, SG
Boudry, CH
Locations
Foster City, US HQ
Fremont, US
Oceanside, US
San Dimas, US
Branford, US
Seattle, US
Locations
Thousand Oaks, US HQ
Sydney, AU
North Ryde, AU
Vienna, AT
Brussels, BE
São Paulo, BR
Burnaby, CA
see more
Locations
Dublin, IE HQ
Buenos Aires, AR
Sydney, AU
Wien, AT
Bruxelles, BE
Chácara Santo Antonio (Zona Sul), BR
Sofia, BG
see more
Locations
Palo Alto, US HQ
Employees
Employees
7,467 5% increase
Employees
9,000
Employees
20,800 8% increase
Employees
23,044 4% decrease
Employees
17 15% decrease
Valuation ($)
Valuation ($)
72.4 b
Valuation ($)
97.6 b
Valuation ($)
128.4 b
Valuation ($)
42.4 b
Valuation ($)
93.3 m
Facebook likes
Facebook likes
6.6 k
Facebook likes
5.4 k
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
N/A
Twitter followers
Twitter followers
19.1 k
Twitter followers
27 k
Twitter followers
65.4 k
Twitter followers
6.2 k
Twitter followers
N/A

Financial

Revenue (est.)
Revenue (est.)
$13b (FY, 2017)
Revenue (est.)
$26.1b (FY, 2017)
Revenue (est.)
$23b (FY, 2016)
Revenue (est.)
$15.2b (FY, 2017)
Revenue (est.)
N/A
Cost of goods
Cost of goods
$461m (FY, 2017)
Cost of goods
$4.4b (FY, 2017)
Cost of goods
$4.2b (FY, 2016)
Cost of goods
$4.7b (FY, 2017)
Cost of goods
N/A
Gross profit
Gross profit
$12.5b (FY, 2017)
Gross profit
$21.7b (FY, 2017)
Gross profit
$18.8b (FY, 2016)
Gross profit
$10.5b (FY, 2017)
Gross profit
N/A
Net income
Net income
$2.9b (FY, 2017)
Net income
$4.6b (FY, 2017)
Net income
$7.7b (FY, 2016)
Net income
$4.3b (FY, 2017)
Net income
($42.4m) (FY, 2017)

Operating

Countries
Countries
N/A
Countries
30 (FY, 2016)
Countries
N/A
Countries
100 (FY, 2017)
Countries
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
3 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
7 (FY, 2017)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
12 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
10 (FY, 2017)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
6 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
15 (FY, 2017)
Phase III Trials Products
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles